Ed Arce
Stock Analyst at WestPark Capital
(3.77)
# 700
Out of 5,148 analysts
376
Total ratings
46.04%
Success rate
9.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.30 | +95.80% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $29.79 | +0.70% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.51 | +8,641.72% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.93 | +982.25% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $8.23 | +629.04% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.31 | +472.52% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $6.49 | +100.31% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.98 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.91 | +558.18% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.03 | +895.73% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $29.84 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.50 | +15,900.00% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.30 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.71 | +460.42% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $92.29 | -21.99% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $432.00 | -6.25% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.55 | -16.03% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $23.39 | +306.16% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.66 | +7.30% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $35.46 | +35.36% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $42.12 | -82.19% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.26 | +1,790.36% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.17 | -8.26% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $40.79 | -38.71% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.61 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.59 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $33.84 | -79.31% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $41.67 | -49.60% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.68 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.30
Upside: +95.80%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $29.79
Upside: +0.70%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.51
Upside: +8,641.72%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.93
Upside: +982.25%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $8.23
Upside: +629.04%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.31
Upside: +472.52%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $6.49
Upside: +100.31%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.98
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.91
Upside: +558.18%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.03
Upside: +895.73%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $29.84
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $1.50
Upside: +15,900.00%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.71
Upside: +460.42%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $92.29
Upside: -21.99%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $432.00
Upside: -6.25%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.55
Upside: -16.03%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $23.39
Upside: +306.16%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.66
Upside: +7.30%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $35.46
Upside: +35.36%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $42.12
Upside: -82.19%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.26
Upside: +1,790.36%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.17
Upside: -8.26%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $40.79
Upside: -38.71%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.61
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.59
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $33.84
Upside: -79.31%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $41.67
Upside: -49.60%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.68
Upside: -